Overview

Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Status:
Not yet recruiting

Trial end date:
2023-09-20

Target enrollment:

Participant gender:

Summary

1. Evaluation of effectiveness: To further evaluate the effectiveness of SI-B001 monotherapy RP2D in patients with unresectable or metastatic colorectal cancer and gastric cancer;To evaluate the efficacy of SI-B001 RP2D and sublow dose combined with chemotherapy in patients with unresectable or metastatic colorectal cancer； 2. Evaluation of safety and tolerability: To further evaluate the safety and tolerability of SI-B001 single-agent RP2D in patients with unresectable or metastatic colorectal cancer and gastric cancer;To evaluate the safety and tolerability of SI-B001 RP2D and sublow dose combined with chemotherapy in patients with unresectable or metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Treatments:

Irinotecan